PCR Firm QuantaLife Raises $17.2M in Series B | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – PCR technology development company QuantaLife announced late Friday that it had closed on a Series B financing round, raising $17.2 million.

The majority of the funds will be used to create a commercialization operation to launch its Droplet Digital PCR platform for the research market and to accelerate development of targeted diagnostic tests, the Pleasanton, Calif.-based company said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.